EGFR and head and neck squamous cell carcinoma: A global Phase III multi-centre clinical trial with ASP-1929 (anti-EGFR antibody cetuximab conjugated to IR700, analogous to RM-1929) in patients with recurrent HNSCC who have failed at least two lines of therapy is ongoing (https://www.clinicaltrials.gov/ct2/show/NCT03769506).